CJC-1295 without DAC (5 mg Vial) Dosage Protocol
CJC-1295 without DAC (also called Modified GRF 1-29) is a 30-amino-acid synthetic GHRH analog with a half-life of ~30 minutes. It produces a discrete GH pulse rather than sustained elevation.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg | 12 units (0.12 mL) |
| Weeks 7–12 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
Frequency: Inject once daily subcutaneously, typically at bedtime to align with natural nocturnal GH pulsatility. For ≤10‑unit (≤0.10 mL) administrations (Weeks 1–4), consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–12 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (CJC-1295 NO DAC, 5 mg each) | 8 weeks ≈ 2 vials 12 weeks ≈ 3 vials 16 weeks ≈ 4 vials |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
CJC-1295 without DAC contains the same four stabilizing amino acid substitutions as the DAC version (D-Ala2, Gln8, Ala15, Leu27) but lacks the albumin-binding linker. The result is a stable, short-acting GHRH analog producing a discrete GH pulse over ~30 minutes.
Common practice combines CJC-1295 with ipamorelin (a GHRP) — the GHRH stimulates GH release while the GHRP synergistically amplifies it, mimicking the body’s natural feedback patterns.
Potential Benefits & Side Effects
Potential Benefits
- Discrete pulsatile GH release mimicking physiological pattern.
- Often combined with ipamorelin for synergistic GH pulses.
- Improvements in sleep quality reported.
- Body composition and recovery effects via sustained protocols.
Side Effect Profile
- Injection-site reactions.
- Mild head flushing or fullness post-dose.
- Transient water retention.
- Hunger increase (some users).
Lifestyle Factors
- Avoid eating for 30+ min after injection — meals blunt GH release.
- Pre-bed dosing aligns with natural GH pulse during slow-wave sleep.
- Resistance training amplifies anabolic effects.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.